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Introduction
Respiratory Syncytial Virus (RSV) is the most important cause of respiratory illness in infants and young children, accounting for more than 100,000 bronchiolitis and pneumonia hospitalizations in the US annually. [1] Worldwide, 33.1 million acute lower respiratory infections and 3.2 million hospitalizations in children under 5 years of age are attributed to RSV each year. [2] In the US ~1-2% of newborns are hospitalized during their first winter, with rates greatest in the first month of life (25.9 per 1000). [3] Risk factors for severe disease include gestational age < 29 weeks, bronchopulmonary disease and symptomatic congenital cardiac disease, while less well defined risks include lack of breast feeding, and exposure to tobacco smoke. However, the majority of hospitalized infants are full-term infants whose only risk factor is young age at the time of infection. [3] A number of severity scores using clinical parameters, including cutaneous oximetry, have been proposed for quantifying illness severity and to guide decisions to hospitalize RSV-infected infants. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, none of the clinically based severity scores have been universally adopted. [14] Reasons may include heterogeneity in the scope and purpose of the score, the ages to which it is applied and concerns about inter-observer variability and subjectivity in interpreting clinical signs, including oximetry, that often are temporally dynamic over short intervals. Finally, the predictive accuracy of clinical severity scores has not been clearly demonstrated. Identification of an objective biomarker that accurately correlates with, or potentially predicts, disease severity could be highly useful in the clinical assessment and management of RSV-infected infants.
We and others have reported a relationship between disease severity and host gene expression in peripheral blood cells, and nasal swab samples, during infection. [15] [16] [17] [18] These results suggest such an approach may allow development of predictive biomarkers to accurately categorize severity and potentially differentiate more vulnerable subjects from those not at risk of severe illness. As part of the AsPIRES study of RSV pathogenesis in healthy full-term infants with primary RSV infection. [19] we recently reported on the feasibility of measuring gene expression of airway cells collected by nasal swab prior to and during RSV infection. [20] In this manuscript, we describe the development of two airway gene expression-based classifiers that are highly correlated with clinical disease severity. This represents a major step in developing a gene expression diagnostic capable of classifying clinical severity in RSV-infected infants.
Methods
Study Subjects: Subjects included RSV infected infants enrolled in the AsPIRES study at the University of Rochester Medical Center (URMC) and Rochester General Hospital (RGH). [19] The Institutional Review Boards of both institutions approved the study, and all parents provided written informed consent. RSV-infected infants came from three cohorts during three winters (October 2012 through April 2015); one cohort included infants hospitalized with RSV, a second cohort was recruited at birth and followed through their first winter for development of RSV infection, and the third cohort was RSV infected infants seen in pediatric offices and emergency departments and managed as outpatients. All subjects were full-term infants undergoing a primary RSV infection during their first winter season. Nasal samples were collected from the inferior nasal turbinate, by gentle brushing with a flocked swab as previously described [20] , during the acute illness visit (visit 1) and at a convalescent visit ~28 after illness onset (visit 2). Illness severity was graded from 0 to 10 using a Global Respiratory Severity Score (GRSS), as previously described. [21] 6 Nasal RNA processing: The process for nasal RNA recovery was previously described. [20] Briefly, following flushing of the nares with saline to remove mucus and cellular debris, a flocked swab was used to recover cells at the level of the turbinates. 
RNAseq data preprocessing
The nasal RNA samples generated an average of 27 ± 6 million total reads, with 66 ± 14% displaying unique mapping to the human genome. Fifteen samples had low yields (< 5 million mapped reads) and were excluded from analyses. Some samples (n=10) with low pair-wise correlation with the other samples (mean < 0.43) were also removed prior to analysis. We filtered the data set to exclude genes with very low normalized expression levels across all subjects. After these quality assurance analyses, the data set consisted of expression data for a total of 13,819 genes in 175 samples.
Because the study spanned three winter seasons, samples were processed in six library batches (Supplementary Figure E1 ). We applied ComBat [22] to remove batch effects prior to statistical analyses. There also were a small proportion of outliers with disproportionally large expression values that could skew the statistical analyses, thus we winsorized the top and bottom 1% of gene expressions. We also excluded from the 7 analysis 131 genes with more than half of their expression values winsorized. Finally, to ensure the robustness of the multivariate classifiers to be developed in this study, we filtered half of the remaining genes based on the inter-quantile range (IQR) criterion. In this way, the remaining 6,844 genes are guaranteed to have a relatively large range of expression values.
Statistical methods:
Descriptive statistics are reported in Table 1 . Discrete variables are summarized in percentages, and continuous variables were summarized as Mean (SE). For continuous variables, we performed 2-sample Welch t-tests to check the equality between the mild and severe groups; for categorical variables, Fisher's exact test was used instead. The nasal gene-expression severity scores we developed in this study were based on multivariate regression analysis with bi-directional stepwise model selection based on Akaike Information Criterion (AIC). Technical details of model development and crossvalidation, including a comparison between AIC-based approach (Strategy 1) and an alternative approach based on elastic-net regression [23, 24] (Strategy 2) can be found in Supplementary Material. All analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA) and the R programming language (version 3.5, R Foundation for Statistical Computing, Vienna, Austria).
Results
Of the 139 RSV-infected infants enrolled in the AsPIRES study, nasal samples were available from 119 subjects during acute infection (day 1-10 of illness) and 81 subjects during convalescence (day 14-28 of illness). Among these 200 samples, 175 samples (106 acute samples and 69 convalescent samples) met sufficient quality to be used for subsequent analyses. Demographic and clinical information for these 106 subjects are provided in Table 1 . The clinical severity score (GRSS) for these subjects ranged from 0 to 10, with 42 subjects considered to have mild disease (GRSS ≤3.5; mean  SE GRSS of 1.63  0.15) and 64 to have severe disease (mean GRSS of 6.13  0.22). There were no significant differences between the mild and severe groups in gender, race, delivery type, breast feeding, or exposure to tobacco smoke. There also was no difference in age at time of infection or in duration of illness at the time of evaluation.
Nasal gene expression correlates of clinical severity during acute illness
The 6,844 genes remaining after data preprocessing and filtering were subjected to the Pearson correlation test to select genes that were significantly correlated with GRSS during acute infection. After applying the Benjamini-Hochberg procedure to control false discovery rate (FDR) at the 0.05 level, 66 significant genes (top correlates) were identified. [25] Using these 66 genes, we applied model selection procedures (see Supplementary Text for more details) to select an initial multivariate regression model for GRSS (Model 1), which was comprised of 39 genes. Using leave-one-out crossvalidation, we showed that this initial model had a relatively good predictive power (77.4% prediction accuracy, or 24 misclassifications) for the dichotomous clinical outcome (mild vs. severe illness).
We performed a principal component analysis (PCA) based on the decomposition of the correlation matrix of the 66 genes most highly correlated with GRSS. We found that the first principal component (PC1) explained a very large proportion (46%) of total variance, with PC2 explaining only 7.4% of the variance. This suggested a strong correlation among the 66 genes, which might reduce the performance of Model 1.
Therefore, we sought to identify supplementary genes, with low correlation with PC1, as additional features to model GRSS (see Supplementary Text for more details). We applied the same model selection procedure to the union of original 66 top correlates 9 and 10 supplementary genes (a total of 76 candidate features), and developed Model 2 that was comprised of 41 genes.
For comparison, we also performed a similar model selection procedure using the 76 genes most correlated with GRSS (original set of 66 top correlates plus the next 10 most significant genes). This Model 3 was comprised of 42 genes.
The performance of each of the three models was evaluated by leave-one-out crossvalidation ( Table 2 ). We found that the incorporation of the supplementary genes into Model 2 (cross-validated prediction accuracy of 89.6%; 11 misclassifications) significantly improved the accuracy compared to Model 1 (24 misclassifications) and
Model 3 (23 misclassifications). Of note, Model 2 contained 5 of the supplementary genes, and we have defined this optimal model as NGSS1 (nasal gene expression severity score 1). Figure 1 , there is a high correlation between NGSS1 and the clinical severity score (GRSS) in the naïve (ρ=0.935) and cross-validated analyses (ρ=0.813).
As shown in
Furthermore, NGSS1 predicted a mean GRSS of 6.22 for severely ill infants (GRSS>3.5) during acute illness ( Figure 2 ). We also calculated the NGSS1 at convalescence (~day 28 after illness onset) for the 54 subjects with data available from both acute and convalescent time points. Since most infants had recovered from their illness by this time, we expected that gene expression would be less informative for classifying disease severity. NGSS1 predicted a significantly lower mean GRSS (2.82, p<.001) for severely ill infants (GRSS>3.5) during convalescence. However, there was no difference in NGSS1 between visits for the mildly ill group (1.96 vs. 2.31, p=0.45).
Stable nasal gene expression correlates of clinical severity
We next developed a nasal gene expression severity score based on genes displaying stable expression across acute illness and convalescence in the 54 subjects with samples from both time points. Specifically, we included only genes whose mean expression levels correlated with disease severity during acute illness, and whose expression did not change significantly from the acute to convalescent stage.
We identified 2127 genes in subjects with mild illness (GRSS ≤3.5) and 1531 genes in subjects with severe illness (GRSS >3.5), based on paired two sample t-test (p > 0.5) and fold change increases or decreases within 10%. Of the total 3658 genes, 689 stable genes were informative in both groups ( Figure 3A) . A quality assurance analysis based on IQR showed that a small subset (n=14) of these genes had relatively small dynamic range in the combined dataset, and were excluded. The remaining 675 stable genes were used in model development.
We applied marginal screening based on Pearson correlation with GRSS for all 106 subjects, and identified 44 marginally significant genes. As in developing NGSS1, we added 5 supplementary genes that are least correlated with them yet still have strong marginal associations with the GRSS. We repeated our regression-based/step-wise model selection procedure and identified 13 genes as Model 4 (also designated as NGSS2). The performance of NGSS2 is provided in Table 2 and illustrated in Figure 3B .
NGSS2 showed a strong and significant correlation with GRSS (ρ=0.741), and a crossvalidated accuracy of 84% (17 misclassifications, Table 2 ). Of note, NGSS1 and NGSS2 do not contain any commonly selected gene, which is expected due to the use of different screening criteria. A full list of genes used in NGSS1 and NGSS2, as well as their estimated linear coefficients in the models, are listed in Supplementary Tables E2   and E3 .
Discussion
Transcriptomic analysis of host cells has proven informative in the study of several respiratory viral infections, including RSV. [15] [16] [17] [18] Most reports have described gene expression correlates of disease in peripheral blood mononuclear cells during infection since RSV pathogenesis is thought to be closely linked to the host's immune response. [26] In two publications from the same group, RSV infection was associated with overexpression of innate immunity genes (neutrophil and interferon genes) and suppression of adaptive T and B cell genes. [15, 17] The investigators used the results to develop a gene-expression based illness score (designated Molecular Distance to Health [MDTH]) that was significantly correlated with a clinical disease severity score, duration of hospitalization and need for supplemental oxygen. Similarly, we reported that gene expression patterns in purified CD4 T cells during infection were correlated with clinical disease severity. [16] In addition to circulating cells, gene expression results from nasal swabs during RSV infection has also been recently reported, with differentially expressed genes correlated with a clinical severity score. [18] The use of nasal specimens in infants is attractive for a number of reasons. Nasal respiratory epithelial cells are the first cells infected and directly initiate early innate immune responses to RSV. The mucosa is also the site of migration of both innate and adaptive immune cells during and after infection. Importantly, we have shown that gene expression in nasal respiratory epithelial cells is highly concordant with published gene expression in lower respiratory tract epithelial cells, and thus should be a reasonable proxy for lung responses to RSV infection. [20] Of practical importance, collection of nasal epithelial cells is relatively non-invasive and simple to perform with minimal discomfort.
The ability to quantify RSV disease severity in young infants has been a frequent and important topic of discussion in the literature, and several approaches have been proposed for evaluation and management of RSV-infected infants. [14] A variety of clinical parameters have been included in different severity scores, with incomplete agreement on the optimal factors to select. One reason is that many clinical signs of RSV infection in young infants, including cutaneous oxymetry measurements, can fluctuate frequently and rapidly during the course of illness, making assessment difficult.
An objective biomarker reliably and continuously correlated with clinical severity could prove useful in determining if an infant could be safely discharged from the emergency department or a physician's office. It might also be valuable as an outcome measure in vaccine efficacy studies or for evaluation of prophylactic or therapeutic medicines.
In this report we describe the use of RNAseq-based analysis of gene expression data from nasal specimens, during and after RSV infection, to develop two nasal geneexpression severity scores (NGSS1 and NGSS2) that are highly correlated with a clinically derived global respiratory severity score (GRSS). We used marginal screening of all genes followed by PCA analysis and step-wise model selection to develop NGSS1, a multivariate linear classifier of severity. In cross-validation analysis, NGSS1 was strongly correlated with GRSS and was a fairly accurate classifier of binary disease severity. Furthermore, the score tracked well with the clinical improvement seen in subjects at day 28 of illness onset. Of particular note, we find that including uncorrelated supplementary genes enhances the prediction accuracy, and recommend this approach as a routine for future classification/prediction analyses based on high-throughput data with substantial correlation.
The 41 NGSS1 genes include cytokines (TNFSF10, IL6, and CXCL2), extracellular matrix proteins (VIM, MMP19, RPS15A, FKBP1A, and VCAN), inflammation regulators 13 (CXCL2, CD163), and components of various signaling processes (GNS, HAVCR2, PTPRC, CTSL, INHBA, IL6, MMP19, CXCL2, SLC39A8, CCDC80, VCAN, CD163).
Many of these genes are only known to be involved in fundamental biological processes and are therefore novel in RSV research, including ST3GAL1 (a type II membrane protein) and ATP10B (ATPase Phospholipid Transporting 10B).
We noted that many of the differentially expressed genes associated with GRSS did not change between the acute and the convalescent time points. It is possible that these genes may simply be slow to return to baseline expression levels, in contrast to those genes selected for NGSS1. However, it occurred to us that "stable" genes could be predictive of severity regardless of when a nasal sample was obtained. We successfully identified a small set of stable genes whose expression patterns are capable of accurately classifying disease severity (NGSS2) beyond acute infection. The rationale for this approach was that these genes were less likely to represent illness-responsive genes and we speculated that they might prove valuable in developing a predictor that was also valid prior to illness onset. While NGSS2 is slightly less accurate than NGSS1 in predicting GRSS during acute illness, the association between NGSS2 and GRSS is still relatively strong. Although speculative, it is possible that determination of NGSS2 in a nasal sample prior to infection might predict disease severity if the infant was subsequently infected. Interestingly, the 13 NGSS2 genes were broadly related to cytoplasmic activities (EXOSC10, PLK2, PPIC, CLDN10, MAP3K13, MT1G, PXN), ATP binding (SEPHS2) and phosphoprotein regulation (BCKDK, PLK2, MAP3K13); activities that may be less directly responsive to acute infection with RSV. These observations suggest that the best nasal transcriptome predictors of respiratory symptoms are not limited to those 14 genes that directly regulate the immune response to RSV infection. Many "down-stream" genes may be able to provide useful information that enhances the predictive power of well-known genes such as IL6 and CXCL2.
There are limitations to our study and conclusions. The number of subjects used is relatively moderate, and a larger confirmatory study will be necessary to validate these results. Secondly, although the NGSS1 declined for the severely ill infants when clinical symptoms had resolved, it would be useful to determine if NGSS1 tracked closely over the course of an illness. If so this would strengthen our conclusion that it may be a potential biomarker for clinical RSV disease severity. The results may not be valid for infants older than 10 months of age when infected with RSV, nor for infants with prematurity or other underlying medical conditions. Finally, speculation that NGSS2, which uses genes that do not vary between the acute illness visit and convalescence, might predict disease severity prior to infection demands careful prospective validation. . Solid dots are subjects with severe symptoms (defined by GRSS>3.5) and empty dots are those with mild symptoms (GRSS≤3.5). 
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